Fri.Apr 26, 2024

Remove biosimilars-drug-development
article thumbnail

European Commission authorises one of first ustekinumab biosimilars in Europe

European Pharmaceutical Review

“approval [of Pyzchiva ® (biosimilar ustekinumab)] of is a crucial step towards offering European patients an additional safe and effective treatment option” Pharmaceutical company Sandoz has announced that the European Commission (EC) has granted marketing authorisation for Pyzchiva ® (biosimilar ustekinumab ).